Biotechnology Stocks Review -- Juno Therapeutics, Amicus Therapeutics, ImmunoGen, CEL-SCI, and Ignyta

Jul 29, 2015, 09:15 ET from www.equityresearchinstitute.com

NEW YORK, July 29, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Juno Therapeutics Inc. (NASDAQ: JUNO), Amicus Therapeutics Inc. (NASDAQ: FOLD), ImmunoGen Inc. (NASDAQ: IMGN), CEL-SCI Corporation (AMEX: CVM), and Ignyta Inc. (NASDAQ: RXDX). Free research report on Juno Therapeutics can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=JUNO On Tuesday, July 28, 2015, the NASDAQ Composite ended at 5,089.21, up 0.98%, the Dow Jones Industrial Average advanced 1.09%, to finish the day at 17,630.27, and the S&P 500 closed at 2,093.25, up 1.24%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.  

Juno Therapeutics Inc.'s stock advanced 1.72%, to close the day at $48.62. The stock recorded a trading volume of 1.40 million shares, below its three months average volume of 2.19 million shares. Over the last one month and over the past three months, Juno Therapeutics Inc.'s shares have gained 4.31% and 2.79%, respectively. However, the stock has lost 6.89% since the start of this year. The company's shares are trading 4.60% below their 200-day moving average. Additionally, Juno Therapeutics Inc. has a Relative Strength Index (RSI) of 43.44. Sign up and read the free notes on JUNO at:

https://www.EquityResearchInstitute.com/reports?keyword=JUNO

On Tuesday, shares in Amicus Therapeutics Inc. recorded a trading volume of 1.32 million shares, lower than their three months average volume of 2.07 million shares. The stock ended the day 4.37% higher at $16.48. Amicus Therapeutics Inc.'s stock has surged 17.30% in the last one month, 54.60% in the previous three months and 98.08% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 20.83% and 67.34%, respectively. Furthermore, shares of Amicus Therapeutics Inc. have an RSI of 65.04. The complimentary notes on FOLD can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=FOLD

ImmunoGen Inc.'s stock gained 3.90%, to close Tuesday's session at $18.10. The stock recorded a trading volume of 0.67 million shares, below its three months average volume of 1.97 million shares. Over the last one month and previous three months, ImmunoGen Inc.'s shares have gained 28.55% and 108.53%, respectively. Additionally, the stock has rallied 196.72% since the start of this year. The company is trading 28.67% and 85.00% above its 50-day and 200-day moving averages, respectively. Furthermore, ImmunoGen Inc.'s stock has an RSI of 65.40. Register for free on Equity Research Institute and access the latest research on IMGN at:

https://www.EquityResearchInstitute.com/reports?keyword=IMGN

CEL-SCI Corp.'s stock finished Tuesday's session 13.29% higher at $0.64. A total of 1.01 million shares were traded, which was above its three months average volume of 0.62 million shares. Over the last one month and since the beginning of this year, CEL-SCI Corp.'s shares have advanced 8.47% and 10.34%, respectively. However, the stock has declined 35.35% in the previous three months. The company's shares are trading below their 50-day and 200-day moving averages by 7.79% and 17.45%, respectively. CEL-SCI Corp.'s stock has an RSI of 49.65. The complete research on CVM is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=CVM

On Tuesday, shares in Ignyta Inc. ended the session 1.28% higher at $14.22. The stock reported a trading volume of 0.40 million shares, below its three months average volume of 0.61 million shares. Although, Ignyta Inc.'s shares have lost 6.26% in the last one month, it has surged 63.07% in the previous three months and 107.59% on YTD basis. The stock is trading 50.95% above its 200-day moving average. Moreover, shares of Ignyta Inc. have an RSI of 48.55. Free in-depth research on RXDX is available at:

https://www.EquityResearchInstitute.com/reports?keyword=RXDX

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com